l e t t e r s
We undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease (AD) involving over 16,000 individuals, the most powerful AD GWAS to date. In stage 1 (3,941 cases and 7,848 controls), we replicated the established association with the apolipoprotein E (APOE) locus (most significant SNP, rs2075650, P = 1.8 × 10 −157 ) and observed genome-wide significant association with SNPs at two loci not previously associated with the disease: at the CLU (also known as APOJ) gene (rs11136000, P = 1.4 × 10 −9 ) and 5 to the PICALM gene (rs3851179, P = 1.9 × 10 −8 ). These associations were replicated in stage 2 (2,023 cases and 2,340 controls), producing compelling evidence for association with Alzheimer's disease in the combined dataset (rs11136000, P = 8.5 × 10 −10 , odds ratio = 0.86; rs3851179, P = 1.3 × 10 −9 , odds ratio = 0.86).
Alzheimer's disease is the most common form of dementia and is highly heritable (with heritability of up to 76%) but genetically complex 1 . Neuropathologically, the disease is characterized by extracellular senile plaques containing β-amyloid (Aβ) and intracellular neurofibrillary tangles containing hyperphosphorylated tau protein 1 . Thus far, four genes have been definitively implicated in the etiology of Alzheimer's disease. Mutations of the genes encoding amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1, PSEN2) cause rare, mendelian forms of the disease, usually with an early onset. However, in the more common form of the disease, only APOE has been established unequivocally as a susceptibility gene 1 . Aiming to identify new Alzheimer's disease loci, several genome-wide association studies (GWAS) have been previously conducted. All have identified strong evidence for Alzheimer's disease risk association to APOE but have found less convincing evidence implicating other genes [2] [3] [4] [5] [6] [7] [8] [9] . This outcome is consistent with the majority of findings from GWAS of other common disease phenotypes, where susceptibility alleles typically have effect sizes with odds ratios (OR) of 1.5 or less, in contrast to that for APOE and Alzheimer's disease (OR ~ 3). Detecting such modest effects requires much larger samples than those used in the GWAS of Alzheimer's disease to date 10 , which have all included fewer than 1,100 cases. Based upon the hypothesis that risk alleles for Alzheimer's disease are likely to confer ORs in the range seen with other common diseases, we undertook a more powerful GWAS than has been carried out to date.
We established a collaborative consortium from Europe and the United States from which we were able to draw upon a combined sample of up to 19,000 subjects (before quality control) and conducted a two-stage study. In stage 1, we genotyped 14,639 subjects on Illumina platforms: 5,715 samples were genotyped using the Illumina 610-quad l e t t e r s chip; genotypes for the remaining subjects were made available to us either from population control datasets or through collaboration and were genotyped on the Illumina HumanHap550 or HumanHap300 BeadChips. Prior to association analysis, all samples and genotypes underwent stringent quality control, which resulted in the elimination of 53,383 autosomal SNPs and 2,850 subjects. Thus, in stage 1, we tested 529,205 autosomal SNPs for association in up to 11,789 subjects (3,941 Alzheimer's disease cases and 7,848 controls, of whom 2,078 were elderly screened controls, see Supplementary Table 1 ). The genomic control inflation factor (λ) 11 was 1.037, suggesting little evidence for residual population stratification.
In addition to the known association of Alzheimer's disease with the APOE locus, GWAS analysis identified two loci associated at a genome-wide level of significance (see Fig. 1 ). Table 1 shows SNPs which were genome-wide significant (GWS) in stage 1. Thirteen GWS SNPs map within or close to the APOE locus on chromosome 19 (P = 3 × 10 −8 -2 × 10 −157 ) and the top five are shown in Table 1 (see  Supplementary Table 2 for the complete list). The other two SNPs represent newly identified associations. One (rs11136000) is located within an intron of CLU (which encodes clusterin) on chromosome 8 (P = 1.4 × 10 −9 , OR = 0.840); the other (rs3851179) is 88.5 kb 5 to PICALM on chromosome 11 (P = 1.9 × 10 −8 , OR = 0.849). Note that there was no significant difference in allele frequencies between elderly, screened controls and population controls for these two SNPs. In stage 2, the two newly identified GWS SNPs were genotyped in an independent sample comprising 2,023 Alzheimer's disease cases and 2,340 age-matched, cognitively screened controls ( Supplementary  Table 3 ). Both were independently associated in this sample (rs11136000, one-tailed P = 0.017, OR = 0.905; rs3851179, one-tailed P = 0.014, OR = 0.897). Meta-analysis of the stage 1 and 2 datasets also produced highly significant evidence of association (rs11136000, P = 8.5 × 10 −10 , OR = 0.861; rs3851179, P = 1.3 × 10 −9 , OR = 0.859, two-tailed, Table 1 ) for CLU and PICALM loci, respectively. We sought further evidence from the Reiman et al. study 9 and the Li et al. study 8 , two publicly available Alzheimer's disease GWAS datasets, but neither of the newly identified GWS SNPs had been previously genotyped or could be imputed. We also note that rs11136000 in CLU showed the most evidence for association with AD in the GWAS of Amouyel and colleagues published in this issue 12 . As secondary analyses, we tested each one for interaction with APOE status and for association with age at onset. No significant interactions of the two newly identified SNPs with APOE status were observed as influencing Alzheimer's disease risk (rs11136000 by APOE-ε4 interaction P = 0.674; rs3851179 by APOE-ε4 interaction P = 0.735). Although we observed significant effects of the GWS SNPs on age at onset, these were limited to SNPs at the APOE locus (data not shown).
In a preliminary attempt to attribute the source of the association to a functional variant, we used publicly available data to identify additional SNPs at each locus that were correlated through linkage disequilibrium (LD) with either of the newly associated SNPs or that Supplementary Table 4 ).
A synonymous SNP (rs7982) in CLU was in strong LD (r 2 = 0.95 in our extension sample) with the GWS SNP and showed a similar level of evidence for association with Alzheimer's disease in our combined stage 1 and 2 sample (meta-analysis P = 8 × 10 −10 ; stage 1 genotypes were imputed). This SNP is in exon 5 of CLU, which encodes part of the beta chain of the clusterin protein and may influence a predicted exon splicing enhancer. We note that Tycko and colleagues 13 previously published a negative association study on the CLU gene and Alzheimer's disease, analyzing four SNPs in an Alzheimer's disease case-control sample of African-American, Hispanic and European descent/non-Hispanic individuals. Although they identified rs7982 through mutation screening (referred to as VB in their study), this SNP was not tested for association in their sample. The four SNPs that were analyzed were rare in individuals of European descent (minor allele frequency <2%) and there was very limited power to detect association in their European descent subsample of 53 Alzheimer's disease cases and 43 controls. As these four SNPs were not genotyped in our GWAS, there is no overlap between the two studies. Several potentially functional SNPs were identified at the PICALM locus. Of these, two showed good evidence for association: rs561655, which is within a putative transcription factor binding site, and rs592297, which is a synonymous SNP in exon 5 of PICALM that may influence a predicted exon splicing enhancer. However, neither of these SNPs showed the strength of evidence for association observed for rs3851179, the GWS SNP at the PICALM locus (rs561655, metaanalysis P = 1 × 10 −7 ; rs592297, meta-analysis P = 2 × 10 −7 ). A number of SNPs in LD with rs3851179 and showing moderate evidence of association in the GWAS (P < 1 × 10 −4 ) were also examined in additional samples, most notably rs541458. This SNP is 8 kb 5 to the PICALM gene and was directly genotyped in the extension sample, the Reiman et al. study and the Li et al. study, with P < 0.05 in each. Following meta-analysis, rs541458 is one of the most significant SNPs (meta-analysis P = 8 × 10 −10 ), a finding that is also supported by the study of Amouyel and colleagues published in this issue (P = 3 × 10 −3 ) 12 . Further genetic analyses will be required to characterize the true nature of the associations observed at these loci.
We also tested whether the number of significant associations observed in the GWAS exceeded what would be expected by chance. Having removed SNPs within the APOE, CLU and PICALM loci from the analysis(see Online Methods), we focused on those that showed the most evidence for association (P < 1 × 10 −5 ; see Table 2 ). Approximately 13 independent signals were observed whereas fewer than 4 would be expected by chance (P = 7.5 × 10 −6 ). This shows suggestive evidence for association with the gene encoding complement receptor 1 (CR1; rs1408077, P = 8.3 × 10 −6 ). We note that Amouyel and colleagues present an independent GWAS of late-onset Alzheimer's disease and report a genome-wide significant association of SNPs in CR1 to Alzheimer's disease 12 . Also noteworthy in our study are the genes encoding bridging integrator 1 (BIN1), which produces a protein involved in synaptic vesicle endoctyosis 14 , and the disabled homolog 1 (DAB1), whose product is involved with tyrosine phosphorylation and microtubule function in neurons 15 . We have also tested over 100 variants highlighted by previous GWAS of Alzheimer's disease for association in our sample (see Supplementary Note for full discussion). These are summarized in Supplementary Table 5 .
Until now, the APOE-ε4 allele was the only consistently replicated genetic risk factor for Alzheimer's disease. It is therefore intriguing that we find compelling evidence for association with CLU, a gene that encodes another major brain apolipoprotein 16 , suggesting that susceptibility genes are not randomly distributed through functional pathways. The predominant form of clusterin is a secreted heterodimeric glycoprotein of 75-80 kDa. The single copy gene spans about 16 kb on chromosome 8p21-p12 and encodes an mRNA of approximately 2 kb that translates into a 449-amino-acid primary polypeptide chain. Clusterin is expressed in all mammalian tissues 17 , and there is strong evidence that CLU expression is elevated in a number of pathological conditions involving injury or chronic inflammation of the brain 18 . In individuals with Alzheimer's disease, CLU expression is reported to be increased in affected cortical areas of the brain and to be present in amyloid plaques and in the cerebrospinal fluid [18] [19] [20] [21] .
Clusterin is a multifunctional molecule. It interacts with the soluble form of Aβ in animal models of disease and binds soluble Aβ in a specific and reversible manner, forming complexes that have been shown to cross the blood-brain barrier [22] [23] [24] [25] . Notably, APOE also appears to act as a molecular chaperone for Aβ and influences when Aβ aggregates and deposits 26 ; APOE also influences Aβ conformation and toxicity 27, 28 . In a similar way, clusterin appears to regulate both the toxicity of Aβ and its conversion into insoluble forms [29] [30] [31] [32] [33] . Furthermore, APOE and clusterin have been shown to cooperate in suppressing Aβ deposition 34 , and they may critically modify 
Aβ clearance at the blood-brain barrier, which could suggest a role for clusterin in the amyloidogenic pathway 35 . Levels of APOE protein appear to be inversely proportional to APOE-ε4 allele dose levels, with protein levels reduced in ε4 homozygotes compared with heterozygotes. Conversely, clusterin levels are increased in proportion to APOE-ε4 allele dose levels, suggesting an induction of clusterin in individuals with low APOE levels 36 .
The second gene locus to show compelling evidence for association with Alzheimer's disease is PICALM (phosphatidylinositolbinding clathrin assembly protein, also known as CALM, clathrin assembly lymphoid-myeloid leukemia gene). PICALM is ubiquitously expressed in all tissue types with prominent expression in neurons, where it is nonselectively distributed at the pre-and postsynaptic structures. It has been shown that like BIN1 (which shows suggestive evidence for association with AD in our sample), the PICALM protein is involved in clathrin-mediated endocytosis (CME), an essential step in the intracellular trafficking of proteins and lipids such as nutrients, growth factors and neurotransmitters [37] [38] [39] . Of relevance to Alzheimer's disease, PICALM appears to be involved in directing the trafficking of VAMP2. VAMP2 is a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein that has a prominent role in the fusion of synaptic vesicles to the presynaptic membrane in neurotransmitter release, a process that is crucial to neuronal function 40 . Brains affected with Alzheimer's disease show a reduced number of synapses, and stereological and biochemical analysis has shown that this reduction in synaptic density correlates better with cognitive decline than with the accumulation of plaques 41 . More recent analysis indicates that synapses within the brains of individuals with Alzheimer's disease may be dysfunctional even before they visibly degenerate 42 . Therefore, we can hypothesize that genetically directed changes in PICALM function result in perturbations at the synapse, possibly through synaptic vesicle cycling, thereby increasing risk for Alzheimer's disease. Alternatively, PICALM could influence Alzheimer's disease risk through APP processing via endocytic pathways, resulting in changes in Aβ levels. Cell culture experiments have shown that full-length APP is retrieved from the cell surface by CME 43 and that inhibition of endocytosis reduces APP internalization and reduces Aβ production and release 44, 45 . Increased synaptic activity is known to lead to the elevated endocytosis of synaptic vesicle proteins, and recent work has provided evidence in vivo that increased CME triggered by increased synaptic activity drives more APP into endocytotic compartments, resulting in an increase of Aβ production and release 46 .
The power of the present study to detect loci of the effect sizes observed in the GWAS for rs11136000 and rs3851179 at a genomewide significance level is 0.74 and 0.57, respectively. However, it is widely acknowledged that effect sizes of significant loci obtained from genome-wide studies are overestimates of the true effects 47 . In the extension study, rs11136000 had an OR of 0.905 and rs3851179 had an OR of 0.897. Assuming that these odds ratios better reflect the true effect sizes associated with these loci, the GWAS has power to detect genome-wide significant association of 0.026 and 0.041, respectively. Thus, it is likely that there are other genes of similar effect sizes that did not reach genome-wide significance. Indeed, we observed many SNPs which, although failing to reach this level of statistical significance, might still reflect true associations with Alzheimer's disease: for example, variants at the CR1 locus, also highlighted by the results of Amouyel and colleagues 12 . As with other GWAS for complex disorders (such as type 2 diabetes, for which 18 susceptibility loci have now been confirmed through GWAS meta-analysis of 54,000 subjects 48 ), additional and larger GWAS may be required to identify remaining susceptibility variants for Alzheimer's disease.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession numbers. GenBank: CLU isoform 1 mRNA, NM_001831.2; CLU isoform 2 mRNA, NM_203339.1; PICALM isoform 1 mRNA, NM_007166.2; PICALM isoform 2 mRNA, NM_001008660.1.
Note: Supplementary information is available on the Nature Genetics website. 
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Sample ascertainment and diagnostic criteria. The study comprised a stage 1 discovery sample of 4,957 Alzheimer's disease cases and 9,682 controls and a stage 2 follow-up sample of 2,023 Alzheimer's disease cases and 2,340 controls. See the Supplementary Note for a complete description of the study subjects.
Stage 1 genotyping.
Genotyping was performed at the Sanger Institute, UK. Two hundred nanograms of input DNA per sample were used and prepared for genotyping using the Illumina Infinium system (Illumina Inc.). Manufacturer's protocols were followed throughout. The Illuminus algorithm for cluster analysis was used for genotype calling 50 .
Stage 1 individual quality control. 4,113 Alzheimer's disease cases and 1,602 controls were genotyped on the Illumina 610-quad chip as part of this study (the 610 group). In addition, 844 Alzheimer's disease cases and 8,080 controls previously genotyped using either the Illumina HumanHap550 or Illumina HumanHap300 were included in the analysis. These genotypes were generated as part of seven different studies, making eight separate groups in total: (i) 610; (ii) Mayo; (iii) 1958 birth cohort (Sanger); (iv) 1958 birth cohort (T1DGC);
(v) ALS control; (vi) Coriell control; (vii) Heinz Nixdorf Recall (HNR) study; (viii) KORA F4. As we used genotype data from multiple sources, it was important to apply stringent quality control (QC) filters, as differential genotyping error rates between groups could result in spurious associations when the data were combined 51, 52 . These filters were applied separately to each of these eight groups to remove poorly performing samples using tools implemented in PLINK version 1.05 (ref. 53). We removed 1,469 individuals with missing genotype rates > 0.01. We also applied a filter based on mean autosomal heterozygosity, excluding 578 individuals with values above or below empirically determined thresholds. Seventy-one individuals with inconsistencies between reported gender and genotype-determined gender and 22 individuals with ambiguous genotypedetermined gender were removed. All individuals passing these QC filters were examined for potential genetic relatedness by calculating identity-by-descent (IBD) estimates for all possible pairs of individuals in PLINK, and removing one of each pair with an IBD estimate ≥0.125 (the level expected for first cousins). IBD estimates were calculated using SNPs that were common to the Illumina 610, 550 and 300 chips with a genotype missing data rate ≤0.01, Hardy-Weinberg P ≥1 × 10 −5 and a minor allele frequency ≥0.01. As a result, 506 individuals were excluded (note that this includes 311 individuals who were included in both the Coriell and ALS control group).
We also sought to detect non-European ancestry. To this end, genotype data from SNPs typed in all cohorts was merged with genotypes at the same SNPs from 210 unrelated European (CEU), Asian (CHB and JPT) and Yoruban (YRI) samples from the HapMap project. Subsequent to removing SNPs in extensive regions of LD (Chr 5:44-51.5 Mb; Chr 6: 25-33.5 Mb; Chr 8: 8-12 Mb; Chr 11: 45-57 Mb) 54 , we further excluded SNPs if any pair within a 50-SNP window had r 2 > 0.2. Genome-wide average identity-by-state (IBS) distance was calculated in PLINK between each pair of individuals in the resulting dataset, based on 57,966 SNPs (all with a genotype missing data rate ≤0.01, Hardy-Weinberg P ≥ 1 × 10 −5 and a minor allele frequency ≥0.01). The resulting matrix of IBS distances was used as input for classical multidimensional scaling (MDS) in R version 2.7.1. When the first two dimensions were extracted and plotted against each other, three clusters were observed as corresponding to the European, Asian and Yoruban samples. Sixteen samples appeared to be ethnic outliers from the European cluster and were excluded from further analysis.
We assessed population structure within the data using principal components analysis as implemented in EIGENSTRAT 55 to infer continuous axes of genetic variation. Eigenvectors were calculated based on the previously described LD-pruned subset of 57,966 SNPs common to all arrays. The EIGENSTRAT program also identifies genetic outliers, which are defined as individuals whose ancestry is at least 6 s.d. from the mean on one of the top ten axes of variation. As a result of this analysis, 188 outliers were identified and excluded. Following sample QC, 3,941 Alzheimer's disease cases and 7,848 controls were included in the analysis.
Stage 1 SNP quality control. Due to unresolved genotype-calling issues with a proportion of SNPs on the sex chromosomes, only autosomal SNPs were included in this analysis (with the exception of rs5984894, an X-chromosome SNP that has previously been associated with Alzheimer's disease 5 ; Supplementary Table 5 ). Individuals either were genotyped on the Illumina 610-quad chip as part of this project, or had been previously genotyped on the Illumina HumanHap550 or the Illumina HumanHap300 array, with the genotypes made available to us. Note that SNPs had already been filtered out of some groups before inclusion in this study. Moreover, where different versions of the same array were used (for example, HumanHap550v1 used to genotype the 1958 birth cohort (Sanger) cohort compared with the HumanHap550v3 array used to genotype the 1958 birth cohort (T1DGC)), only SNPs common to both versions were considered as present on that array. As such, SNPs included in our analysis fell into four different categories: (i) 266,714 SNPs common to all three arrays and genotyped in all individuals; (ii) 202,516 SNPs common to the 610 and 550 arrays, but not present or without genotypes in individuals typed on the 300 array; (iii) 7,744 SNPs common to the 610 and 300 arrays, but not present or without genotypes in individuals typed on the 550 array; (iv) 105,614 SNPs with genotypes only in the 610 data.
We assessed the effects of different missing data rates and Hardy-Weinberg filters, aiming to remove poorly performing SNPs without excluding markers that may show genuine association with Alzheimer's disease. For each of the four SNP categories, markers were excluded if they had a minor allele frequency (MAF) <0.01 or a Hardy-Weinberg P ≤ 1 × 10 −5 in either cases or controls. SNPs with a MAF ≥0.05 were excluded if they had a genotype missing rate of >0.03 in either cases or controls; for SNPs with a MAF between 0.01 and 0.05, a more stringent genotype missing rate threshold of 0.01 was used. As a result of this basic SNP QC, 43,542 SNPs were excluded.
Ten principal components (PCs) were extracted using EIGENSTRAT, as previously described. To determine whether the PCs could assuage any population structure within our sample, we performed logistic regression tests of association with Alzheimer's disease, sequentially including between 0 and 10 of the top PCs as covariates. The impact of including the PCs was evaluated by calculating the genomic control inflation factor, λ 11 . We found that including the first four PCs as covariates had the maximum impact on λ.
To minimize inter-chip and inter-cohort differences that could result in an inflation of type I error rate, minor allele frequencies were compared between controls in the different groups using logistic regression analysis, incorporating the top four PCs as covariates as previously described. Comparisons were performed only between individuals from the same geographical region (that is, British Isles, Germany or USA). For each of the four categories of SNPs, a quantile-quantile (Q-Q) plot was produced for each cohort control comparison, and the significance threshold used to exclude SNPs was based on where the observed χ 2 statistics departed from the null expectation. A further 9,828 SNPs were excluded as a result of these comparisons. Thus, a total of 529,218 autosomal SNPs were analyzed for association with Alzheimer's disease in this study.
Stage 1 statistical analysis. SNPs were tested for association with Alzheimer's disease using logistic regression, assuming an additive model. Covariates were included in the logistic regression analysis to allow for geographical region and chip, that is, to distinguish between (i) individuals from the British Isles, (ii) individuals from Germany, (iii) individuals from the United States typed on the 610 or 550 chip and (iv) individuals from the United States typed on the 300 chip. It was not possible to include a covariate for each chip, as only controls were genotyped on the 550 chip. Similarly, it was not possible to include a covariate for each of the eight groups, as only two included both cases and controls (610 and Mayo groups). The first four PCs extracted from EIGENSTRAT were also included as covariates, as previously described. Following analysis, 130 cluster plots were visually inspected for SNPs with a P value ≤ 1 × 10 −4 . Thirteen SNPs showing poorly formed clusters were excluded. Thus, our analysis was based on 529,205 SNPs, and a conservative genome-wide significance threshold of 0.05/529205 = 9.4 × 10 −8 was used. The overall λ was calculated to be 1.037. Population attributable risk (the expected reduction in disease load following removal of a risk factor) was calculated for GWS SNPs according to the following formula:
Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer
